Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Bupivacaine HCL TAP Block in Breast Reconstruction
NCT02662036Phase 4Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Analgesic Effectiveness of Liposomal Bupivacaine (Exparel) Versus Bupivacaine HCl as Measured by Opioid Use During Hospital Stay. Started Feb 2016; status: terminated.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02662036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662036.